Advertisement

A Bayesian Constancy-Enforced Non-Inferiority Design in Medical Device Trials with a Binary Endpoint

  • Ying YangEmail author
  • Yunling Xu
  • Nelson T. Lu
  • Ram C. Tiwari
Chapter
Part of the ICSA Book Series in Statistics book series (ICSABSS)

Abstract

Non-inferiority trials are commonly seen in medical device trials. However, the violation of the constancy assumption could be a serious concern. Some approaches have been proposed to address the impact of violation of the constancy assumption on the validity of a non-inferiority trial such as prevention through good trial conduct and adjustment through analysis. In this paper, we propose a new approach via adding a companion constancy test to the non-inferiority test that consequently protects the validity of a non-inferiority trial under Bayesian framework. In addition, as some clinical data from historical studies are available for the active control prior to the start of the investigational study, we consider two different methods to borrow the available information. We use a simulation study to assess the performance of the proposed approach.

Keywords

Non-inferiority Constancy assumption Companion test Bayesian borrowing Historical data 

References

  1. Chen, M.H., Ibrahim, J.G.: The relationship between the power prior and hierarchical models. Bayesian Anal. 1(3), 551–574 (2006)MathSciNetCrossRefGoogle Scholar
  2. D’Agostino, R.B., Massaro, J.M., Sullivan, L.M.: Non-inferiority trials: design concepts and issues-the encounters of academic consultants in statistics. Stat. Med. 22, 169–186 (2003)CrossRefGoogle Scholar
  3. FDA. Use of Bayesian statistics in medical device clinical trials. https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm071121.pdf (2010)
  4. FDA. Design considerations for pivotal clinical investigations for medical devices. https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM373766.pdf (2013)
  5. FDA. Non-inferiority clinical trials to establish effectiveness. https://www.fda.gov/downloads/Drugs/Guidances/UCM202140.pdf (2016)
  6. Fleming, T.R.: Current issues in non-inferiority trials. Stat. Med. 27, 317–322 (2008)MathSciNetCrossRefGoogle Scholar
  7. Gamalo, M.A., Tiwari, R.C., LaVange, L.M.: Bayesian approach to the design and analysis of non-inferiority trials for anti-infective products. Pharm. Stat. 13, 25–40 (2013)CrossRefGoogle Scholar
  8. Gamalo-Siebers, M., Gao, A.J., Lakshminarayanan, M., Liu, G.H., Natanegara, F., Railkar, R., Schmidli, H., Song, G.C.: Bayesian methods for the design and analysis of noninferiority trials. J. Biopharm. Stat. 26, 823–841 (2016)CrossRefGoogle Scholar
  9. Gelman, A.: Prior distributions for variance parameters in hierarchical models. Bayesian Anal. 1(3), 515–533 (2006)MathSciNetCrossRefGoogle Scholar
  10. Hsu, Y.Y., Zalkikar, J., Tiwari, R.C.: Hierarchical Bayes approach for subgroup analysis. Stat. Methods Med. Res. 28(1), 275–288 (2019)MathSciNetCrossRefGoogle Scholar
  11. Hung, H.M.J., Wang, S.-J., Tsong, Y., Lawrence, J., O’Neil, R.T.: Some fundamental issues with non-inferiority testing in active controlled trials. Stat. Med. 22, 213–225 (2003)CrossRefGoogle Scholar
  12. Ibrahim, J.G., Chen, M.H., Gwon, Y.J., Chen, F.: The power prior: theory and applications. Stat. Med. 34, 3724–3749 (2015)MathSciNetCrossRefGoogle Scholar
  13. Ibrahim, J.G., Chen, M.-H.: Power prior distributions for regression models. Stat. Sci. 15(1), 46–60 (2000)MathSciNetCrossRefGoogle Scholar
  14. Koopmeiners, J.S., Hobbs, B.P.: Detecting and accounting for violations of the constancy assumption in non-inferiority clinical trials. Stat. Methods Med. Res. 27(5) 1547–1558 (2018)MathSciNetCrossRefGoogle Scholar
  15. Liu, Q., Li, Y., Odem-Davis, K.: On robustness of non-inferiority clinical trial designs against bias, variability, and nonconstancy. J. Biopharm. Stat. 25, 206–225 (2015)CrossRefGoogle Scholar
  16. Lu, N.T., Xu, Y.L., Yang, Y.: Incorporating a companion test into the non-inferiority design of medical device trials. J. Biopharm. Stat. 29(1), 143–150 (2019)CrossRefGoogle Scholar
  17. Nie, L., Soon, G.: A covariate-adjustment regression model approach to noninferiority margin definition. Stat. Med. 29, 1107–1113 (2010)MathSciNetGoogle Scholar
  18. Odem-Davis, K., Fleming, T.R.: Adjusting for unknown bias in noninferiority clinical trials. Stat. Biopharm. Res. 5, 248–258 (2013)CrossRefGoogle Scholar
  19. Wang, S.-J., Hung, H.M.J.: TACT method for non-inferiority testing in active controlled trials. Stat. Med. 22, 227–238 (2003)CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Ying Yang
    • 1
    Email author
  • Yunling Xu
    • 1
  • Nelson T. Lu
    • 1
  • Ram C. Tiwari
    • 1
  1. 1.Division of Biostatistics, Office of Surveillance and BiometricsCenter for Devices and Radiological Health, Food and Drug AdministrationSilver SpringUSA

Personalised recommendations